Evotec and Boehringer Ingelheim Significantly Expand and Extend their Joint Drug Discovery Collaboration

18-Jan-2006

Evotec AG announced that effective from 1 January 2006 Evotec and Boehringer Ingelheim GmbH will significantly expand their drug discovery collaboration initiated in September 2004, effectively doubling the already sizeable programme. At the same time, the collaboration that was originally projected to end in August 2007 was extended to the end of 2008.

Evotec and Boehringer aim to jointly identify and develop pre-clinical development candidates suitable for future selection as drug candidates for clinical testing. While the original contract was exclusively targeted at therapeutics acting on G-Protein Coupled Receptors (GPCRs), the extension also includes targets from different target classes, including ion channels and enzymes. Boehringer will have the ownership and global responsibility for all clinical development activities, manufacture and commercialisation of the compounds identified in the collaboration.

As compensation for Evotec's contributions to the programme, Evotec receives ongoing research payments from Boehringer. In addition, Boehringer will pay to Evotec pre-clinical and clinical milestones as well as royalties on drugs discovered in the collaboration. The first project milestone was successfully announced in June 2005, less than one year after the start of this partnership.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances